Coxibs, selective inhibitors of cyclooxygenase-2 (COX-2), increase the risk of myocardial infarction and stroke [1–3], prompting concern for patients with established cardiovascular disease. The gene discussed is PTGS2; the disease is cardiovascular disorder.